June 2026 Biopharma Hedge Fund Stock Picks: CLDX, ORIC, and CMPX

For June 2026, BPIQ’s Hedge Fund Stock Picks highlight three biopharma names with very different profiles: Celldex Therapeutics, ORIC Pharmaceuticals, and Compass Therapeutics.

CLDX offers a later-stage immunology catalyst setup with an M&A-validated target area. ORIC provides a multi-shot precision oncology story across lung cancer and prostate cancer. CMPX brings the highest risk/reward around a lead asset approaching its first regulatory filing and earlier stage assets.

To be a top hedge fund pick all 3 of these companies are among the most widely held biopharma stocks by the top 36 top biopharma-focused hedge funds. Of course, hedge fund ownership does not guarantee a stock will be a good investment. However, based on over 20 years of experience investing in different strategies for public biopharma companies, we have found that following these top biopharma hedge fund holdings is a powerful strategy for identifying biopharma stocks worth your attention and further diligence.

CLDX: The Later-Stage Immunology Pick

Celldex Therapeutics is the more mature catalyst story among the June 2026 HF Stock Picks.

Thus, among our June 2026 Hedge Fund Picks, CLDX is better suited for investors looking for a more established clinical-stage biopharma company.

The company has:

• A lead asset with:

  • positive Phase 2 data already on the board

  • a pivotal Phase 3 readout ahead

  • an M&A-validated target

• Several  early stage clinical assets

• a cash runway to support these trials

The key risk is that Phase 3 must confirm the Phase 2 profile on registrational endpoints. Chronic spontaneous urticaria is also becoming a more competitive field, with multiple mechanisms advancing across the space.

Still, among the June 2026 picks, CLDX looks like the cleaner later-stage catalyst story.

Bottom line: CLDX may appeal to investors looking for a more validated biotech catalyst setup, with pivotal data ahead and a broader mast-cell platform behind it.

ORIC: The Multi-Shot Precision Oncology Pick

ORIC Pharmaceuticals is better suited for investors looking for a higher-risk oncology name with multiple shots on goal.

The company has:

• A lead asset with:

  • positive Phase 1b response data already on the board

  •  brain-penetrant positioning with strong intracranial activity

  • multiple second-half 2026 first-line NSCLC readouts ahead

  •  a potentially differentiated profile in EGFR/HER2 exon 20 insertion NSCLC

• A second clinical program with:

  • metastatic castration-resistant prostate cancer with a company-guided Phase 3 initiation expected in 1H 2026

The risk is that ORIC still needs to confirm early open-label data in larger, more definitive settings. The NSCLC exon 20 space is also competitive, with other programs advancing toward important readouts and regulatory milestones.

There is also execution risk around timing. Some of the upcoming events are company-guided rather than fully confirmed catalyst dates.

Bottom line: ORIC should appeal to investors looking for a multi-shot oncology setup, where upside depends on continued execution across both lung cancer and prostate cancer programs.

CMPX: The Small-Cap High Risk/Reward Cancer Pick

Compass Therapeutics is the highest risk/reward profile among the three June 2026 picks.

CMPX is best for investors looking for small-cap biotech leverage and willing to accept greater risk.

The company has:

• A lead asset with

  • positive randomized Phase 2/3 data

  • approaching its first BLA submission

• Three other mono and bispecific antibody cancer assets with readouts in Q4 2026

• a low enterprise value relative to the upcoming regulatory event

• a cash runway that supports the near-term development plan

Near-term value is heavily concentrated in tovecimig. The commercial opportunity in second-line biliary tract cancer may be more limited than larger oncology indications. The magnitude of the PFS benefit, the lack of statistically significant overall survival so far, FDA feedback, BLA acceptance, and eventual market adoption all remain important diligence points.

Bottom line: CMPX may appeal to investors looking for a high-risk, high-upside small-cap oncology setup with meaningful regulatory leverage.

Final Takeaway

The June 2026 BPIQ HF Stock Picks show three different ways biotech hedge fund consensus can appear.

CLDX offers a more validated later-stage immunology setup. ORIC offers a multi-program precision oncology setup. CMPX offers a high risk/reward small-cap regulatory leverage setup. All three have strong hedge fund support. All three have upcoming catalysts.

---

This article is not investment, tax, or legal advice. Please do your own diligence and seek advice from professional advisors representing your interests.

Article history:

First published 6/11/26 EJV, RF